Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients.

ABSTRACT:

Background

Deferasirox (DFX) is commonly used to reduce the chronic iron overload (IO) in pediatric patients. However, the drug is characterized by a large pharmacokinetic variability and approximately 10% of patients may discontinue the treatment due to toxicities. Therefore, the present retrospective study investigated possible correlations between DFX pharmacokinetics and drug-associated toxicities in 39 children (26 males), aged 2-17 years, who underwent an allogeneic hematopoietic stem cell transplantation.

Methods

IO was diagnosed by an abdominal magnetic resonance imaging and DFX was started at a median dose of 500 mg/day. DFX plasma concentrations were measured by a high performance liquid chromatographic method with UV detection and they were analysed by nonlinear m

SUBMITTER: Galeotti L 

PROVIDER: S-EPMC8401444 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature